Consistent with these findings, PASI scoring quantified 50–150% elevations across all disease progression metrics in the IL-1β rescue group versus controls, including erythema intensity (p = 0.008), scaling severity (p = 0.003), and lesional induration (p < 0.001) (Fig. 8B). This evidence concerns the gene IL1B and Erythema.